City
Epaper

US FDA declines to authorise antidepressant fluvoxamine for Covid

By IANS | Updated: May 17, 2022 19:00 IST

New York, May 17 The US Food and Drug Administration has declined to approve antidepressant fluvoxamine as a ...

Open in App

New York, May 17 The US Food and Drug Administration has declined to approve antidepressant fluvoxamine as a treatment for Covid-19 as data is insufficient to conclude its effectiveness against the virus.

Fluvoxamine has been a low-cost and safe drug typically used in forms of depression and related disorders. Some studies claimed that the drug has the potential to reduce the cytokine storm in Covid-19 patients. Cytokine storms are severe immune responses to Covid-19 that can cause potentially lethal organ damage.

But the drug regulator, in a document, stated: "Based on the review of available scientific evidence, the FDA has determined that the data is insufficient to conclude that fluvoxamine may be effective in the treatment of non-hospitalised patients with Covid-19 to prevent progression to severe disease and/or hospitalisation."

"Therefore, FDA has determined that the criteria for issuance of an EUA are not met and is declining to issue an EUA covering fluvoxamine for the treatment of Covid-19 at this time," it added.

Currently, fluvoxamine is FDA-approved for the treatment of obsessions and compulsions in patients with obsessive compulsive disorder (OCD) in children 8-17 years of age and adults.

But in December, 2021, Dr. David R Boulware, a professor at University of Minnesota in the US, submitted a request to the FDA to grant emergency use authorization (EUA) to fluvoxamine for the outpatient treatment of Covid positive persons above 24 years of age to prevent progression to severe disease and/or hospitalisation.

The agency said it reviewed available information derived from several clinical trials investigating the use of fluvoxamine for the treatment of Covid-19.

It noted that "the treatment benefit of fluvoxamine was not persuasive when focusing on clinically meaningful outcomes", meaning no reduction in hospitalisations and deaths.

Fluvoxamine is a selective serotonin reuptake inhibitor (SSRI), currently used to treat mental health conditions such as depression and obsessive-compulsive disorders. It has been used since the 1990s for various conditions and its safety profile is well-known.

Disclaimer: This post has been auto-published from an agency feed without any modifications to the text and has not been reviewed by an editor

Tags: David R. BoulwarefdaUs Food And Drug Administration
Open in App

Related Stories

PunePune: Action to Be Taken Against Use of Calcium Carbide to Ripen Mangoes

MumbaiMumbai: FDA Seizes Medicines Worth Rs 61.95 Lakh from Ghatkopar-Based Drug Firm

MumbaiMumbai: FDA Cracks Down on Adulterated Milk at City Entry Points; Over 1.5 Lakh Litres Inspected

MaharashtraChandrapur Shops Caught Selling Fake Paneer; FDA Seizes 472 Kg of Cheese Analogue

MumbaiMumbai FDA Allows Homeopathy Doctors to Prescribe Allopathic Medicines; IMA Opposes Decision

Health Realted Stories

HealthCentre extends financial aid to indigenous indoor air purification solution

HealthChildhood exposure to bacterial toxin can trigger Colorectal cancer among the young: Study

HealthIndia achieves breakthrough in gene therapy for haemophilia: Minister

LifestyleWalking Tips for Summer: Know the Best time to Walk to Avoid Heatstroke

HealthCentre launches campaign to achieve 100 pc Measles-Rubella immunisation coverage